Pathways Regulating Lymphatic Vessel Permeability and Valve Formation
调节淋巴管渗透性和瓣膜形成的途径
基本信息
- 批准号:10599157
- 负责人:
- 金额:$ 42.92万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-05-24 至 2025-04-30
- 项目状态:未结题
- 来源:
- 关键词:AddressAlbuminsAreaBiological AssayBlood VesselsBreedingCancer SurvivorCardiovascular DiseasesCicatrixDataDeveloped CountriesDevelopmentDiabetes MellitusDiseaseEdemaEventExcisionExtravasationFOXC2 geneFibrosisFunctional disorderGene MutationGeneticGrowthHealthHumanImpairmentInfectionKDR geneKnock-outKnockout MiceLifeLiquid substanceLymphLymphaticLymphatic EndotheliumLymphedemaMaintenanceMassageMethodsMolecularMusNitric OxideNuclear TranslocationObesityPainPalliative CarePathogenesisPathway interactionsPatientsPermeabilityPersonsPhysiologicalPredispositionProteinsPublishingRiskRoleSignal TransductionSignaling MoleculeSignaling ProteinStructureSwellingTamoxifenTestingTimeTissuesTransgenic MiceWorkarmbeta catenincadherin 5cancer surgerydraining lymph nodeeffective therapyexperimental studyhypercholesterolemiainfection riskinnovationlymph flowlymph nodeslymphatic imaginglymphatic valvelymphatic vasculaturelymphatic vesselmalignant breast neoplasmmechanotransductionnew therapeutic targetpreservationpreventresponseshear stresstargeted treatmenttherapeutic targettranscription factor
项目摘要
Lymphedema is a lifelong disease characterized by tissue swelling, fibrosis, and increased risk of infections for
millions of people in the US and is caused by impaired lymph flow. While congenital gene mutations can cause
lymphedema, breast cancer surgery to remove lymph nodes is the most common cause in developed
countries. Analyses of lymphatic vessels in human patients have revealed retrograde lymph flow and leaky
lymphatic vessels, indicating valve dysfunction. An effective treatment for lymphedema is currently lacking, but
targeted therapies to restore lymphatic valve function and prevent leakage would ideally enhance lymph flow in
these patients. However, surprisingly little is known about the molecules or mechanisms regulating lymphatic
vessel permeability because no methods existed to quantify lymphatic permeability. To address this gap, our
lab recently developed the only approach to quantify the permeability of lymphatic vessels from knockout mice.
The current proposal has combined this new physiological approach with inducible, tissue-specific knockout
and transgenic mice to investigate lymphatic endothelial junction protein signaling. Our results suggest a new
paradigm – that a single junction protein is capable of regulating both valve development and lymphatic vessel
permeability. The central hypothesis of this proposal is that constant signaling through the junction protein, VE-
cadherin, maintains normal valve structure and lymphatic barrier function. Our findings show that VE-cadherin
is required for lifelong valve maintenance by providing persistent cell signals in response to shear stress, and
the same pathway prevents excessive lymphatic permeability (i.e. leakage). The central hypothesis will be
tested by the following two aims investigating the role of lymphatic junction proteins: Aim 1 will test whether
VE-cadherin regulates lymphatic valve formation and maintenance by transducing shear stress into
intracellular signals (i.e. mechanotransduction), and Aim 2 will determine whether the same
mechanotransduction signaling events regulate lymphatic permeability in the valve and non-valve areas of
lymphatic collecting vessels. The completion of these aims will lead to new strategies to target VE-cadherin
signaling to prevent the development of lymphedema in at-risk patients.
淋巴水肿是一种终身性疾病,其特征在于组织肿胀、纤维化和感染的风险增加。
在美国有数百万人,是由淋巴液流动受损引起的。虽然先天性基因突变会导致
乳腺癌手术切除淋巴结是最常见的原因,在发达国家
国家对人类患者的淋巴管的分析揭示了逆行淋巴流和渗漏。
淋巴管表明瓣膜功能障碍目前缺乏有效的治疗水肿的方法,但
恢复淋巴瓣功能和防止渗漏的靶向治疗将理想地增强淋巴流动,
这些病人。然而,令人惊讶的是,人们对调节淋巴细胞增殖的分子或机制知之甚少。
血管通透性,因为没有方法可以量化淋巴通透性。为了弥补这一差距,我们
实验室最近开发了唯一的方法来量化基因敲除小鼠淋巴管的渗透性。
目前的建议结合了这种新的生理方法与诱导,组织特异性敲除
和转基因小鼠来研究淋巴管内皮连接蛋白信号传导。我们的研究结果表明,
范例-单个连接蛋白能够调节瓣膜发育和淋巴管
磁导率该提议的中心假设是,通过连接蛋白VE-1的恒定信号传导,
钙粘蛋白,维持正常的瓣膜结构和淋巴屏障功能。我们的研究结果表明,VE-钙粘蛋白
通过响应剪切应力提供持续的细胞信号,
相同的途径可以防止过度的淋巴渗透性(即渗漏)。核心假设是
通过以下两个目标进行测试,研究淋巴结蛋白的作用:目标1将测试是否
VE-钙粘蛋白通过将切应力转换为
细胞内信号(即机械转导),Aim 2将确定是否相同
机械转导信号传导事件调节淋巴管的瓣膜和非瓣膜区域的淋巴渗透性,
淋巴集合管这些目标的实现将导致针对VE-钙粘蛋白的新策略
信号以防止高危患者发生水肿。
项目成果
期刊论文数量(4)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Endothelial Nitric Oxide Synthase Regulates Lymphatic Valve Specification By Controlling β - catenin Signaling During Embryogenesis.
内皮一氧化氮合酶通过控制胚胎发生过程中的β-连环蛋白信号传导来调节淋巴瓣膜规格。
- DOI:10.1101/2023.04.10.536303
- 发表时间:2023
- 期刊:
- 影响因子:0
- 作者:Iyer,Drishya;Mastrogiacomo,Diandra;Li,Kunyu;Banerjee,Richa;Yang,Ying;Scallan,JoshuaP
- 通讯作者:Scallan,JoshuaP
VE-Cadherin and Vesicles Differentially Regulate Lymphatic Vascular Permeability to Solutes of Various Sizes.
- DOI:10.3389/fphys.2021.687563
- 发表时间:2021
- 期刊:
- 影响因子:4
- 作者:Jannaway M;Scallan JP
- 通讯作者:Scallan JP
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Joshua Paul SCALLAN其他文献
Joshua Paul SCALLAN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Joshua Paul SCALLAN', 18)}}的其他基金
VEGFR Signaling Controls Lymphatic Junctions
VEGFR 信号传导控制淋巴连接
- 批准号:
10502986 - 财政年份:2022
- 资助金额:
$ 42.92万 - 项目类别:
VEGFR Signaling Controls Lymphatic Junctions
VEGFR 信号传导控制淋巴连接
- 批准号:
10642854 - 财政年份:2022
- 资助金额:
$ 42.92万 - 项目类别:
Pathways Regulating Lymphatic Vessel Permeability and Valve Formation
调节淋巴管渗透性和瓣膜形成的途径
- 批准号:
10400033 - 财政年份:2019
- 资助金额:
$ 42.92万 - 项目类别:
Lymphatic Endothelial Permeability as a Regulator of Mesenteric Adipose Depositio
淋巴内皮渗透性作为肠系膜脂肪沉积的调节器
- 批准号:
8765310 - 财政年份:2014
- 资助金额:
$ 42.92万 - 项目类别:
Lymphatic Endothelial Permeability as a Regulator of Mesenteric Adipose Depositio
淋巴内皮渗透性作为肠系膜脂肪沉积的调节器
- 批准号:
8918733 - 财政年份:2014
- 资助金额:
$ 42.92万 - 项目类别:
Lymphatic Endothelial Permeability as a Regulator of Mesenteric Adipose Depositio
淋巴内皮渗透性作为肠系膜脂肪沉积的调节器
- 批准号:
9259810 - 财政年份:2014
- 资助金额:
$ 42.92万 - 项目类别:
相似海外基金
Exploiting and enhancing IgE-binding epitopes of the 2S albumins of peanuts and tree nuts
利用和增强花生和坚果 2S 白蛋白的 IgE 结合表位
- 批准号:
10685312 - 财政年份:2021
- 资助金额:
$ 42.92万 - 项目类别:
Exploiting and enhancing IgE-binding epitopes of the 2S albumins of peanuts and tree nuts
利用和增强花生和坚果 2S 白蛋白的 IgE 结合表位
- 批准号:
10490872 - 财政年份:2021
- 资助金额:
$ 42.92万 - 项目类别:
Exploiting and enhancing IgE-binding epitopes of the 2S albumins of peanuts and tree nuts
利用和增强花生和坚果 2S 白蛋白的 IgE 结合表位
- 批准号:
10345963 - 财政年份:2021
- 资助金额:
$ 42.92万 - 项目类别:
Development of Highly Functionalized Serum Albumins as Boron Delivery Carries to Tumor for Neutron Capture Therapy
开发高功能化血清白蛋白作为硼输送至肿瘤以进行中子捕获治疗
- 批准号:
17H02202 - 财政年份:2017
- 资助金额:
$ 42.92万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Studies on Asymmetric Nitroaldol Reaction using mutant albumins
突变体白蛋白不对称硝醛醇反应的研究
- 批准号:
16K05706 - 财政年份:2016
- 资助金额:
$ 42.92万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
SPIN LABELING STUDIES OF NORMAL RECOMBINANT & MUTANT HUMAN SERUM ALBUMINS
正常重组的旋转标记研究
- 批准号:
6118869 - 财政年份:1999
- 资助金额:
$ 42.92万 - 项目类别:
COPPER BINDING OF COMMERCIAL, NORMAL RECOMBINANT, & MUTANT HUMAN SERUM ALBUMINS
商业、正常重组的铜结合,
- 批准号:
6118864 - 财政年份:1999
- 资助金额:
$ 42.92万 - 项目类别:
Structure and Metabolism of the Serum Albumins Characteristic of Bisalbuminemia in Fowl
家禽双清蛋白血症血清白蛋白的结构与代谢特征
- 批准号:
67B6472 - 财政年份:1967
- 资助金额:
$ 42.92万 - 项目类别:
Structure and Metabolism of the Serum Albumins Characteristic of Bisalbuminemia
双清蛋白血症血清白蛋白的结构和代谢特征
- 批准号:
65B3344 - 财政年份:1965
- 资助金额:
$ 42.92万 - 项目类别: